Novo Nordisk to build manufacturing facility in Iran
The plant will manufacture FlexPen prefilled devices.
Novo Nordisk has that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled devices in Iran.
The project is expected to last 5 years and represents a Novo Nordisk investment of approximately 70 million euros. The production will function in compliance with GMP, which will ensure the quality and reliability of the products.
"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products," said Ole Moelskov Bech, corporate vice president of Novo Nordisk Business Area Near East.
With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.